Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. announced positive results from its 13-week Phase II study of ASC30, an oral GLP-1 receptor agonist for obesity treatment. The study demonstrated significant weight loss and improved gastrointestinal tolerability compared to placebo, with no severe adverse events reported. These findings suggest a potential best-in-class profile for ASC30, positioning Ascletis favorably in the obesity treatment market as they plan to advance to Phase III trials.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$14.00 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is engaged in the research and development of oral small molecule drugs, with a particular emphasis on GLP-1 receptor agonists for obesity treatment.
Average Trading Volume: 7,180,014
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.64B
For a thorough assessment of 1672 stock, go to TipRanks’ Stock Analysis page.